Corregene Biotechnology Co., Ltd
4 clinical trials · Sponsor
◉ Watch Corregene Biotechnology Co., Ltd
| Record | Firm | Date |
|---|---|---|
| A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors (NCT07583316) | Corregene Biotechnology Co., Ltd | 2026-05-29 |
| KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (NCT06767046) | Corregene Biotechnology Co., Ltd | 2025-02-18 |
| CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers (NCT06358053) | Corregene Biotechnology Co., Ltd | 2024-04-15 |
| CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers (NCT05122221) | Corregene Biotechnology Co., Ltd | 2022-07-17 |
Track Corregene Biotechnology Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.